Pathways were analyzed via metabolic assays, The Cancer Genome Atlas (TCGA) breast cancer datasets, and Harmonizome gene sets.<h4>Results</h4>231RR cells exhibited enhanced CSC traits and upregulated SRC/STAT3 signaling, with heightened sensitivity to SRC/STAT3 inhibitors. The gene discussed is STAT3; the disease is breast carcinoma.